cp wire

CP Wire Articles

  • The new PDUFA date is March 19, 2019
  • The FDA has not requested any additional clinical data or any additional information from the Company as part of the extension


... read more

Tue, 11/20/18 - 09:23 am
admin

Inflazome, a pioneering inflammasome company developing small molecule drugs that block harmful inflammation, today announces the successful completion of a Series B financing round of €40 million... read more

Mon, 11/19/18 - 09:19 am
admin
  • Without a successful bone marrow transplant, mortality in patients with severe LAD-I is 60-75% prior to the age of 2
  • The disease occurs in approximately 1 in 1 million births... read more
Mon, 11/19/18 - 08:59 am
admin

Immunicum will initiate a study of ilixadencel in the fourth quarter of 2018. Following completion of the Ib portion of the study, a Phase II study will be conducted using the checkpoint inhibitor... read more

Fri, 11/16/18 - 08:28 am
admin

UCB, a global biopharmaceutical company working in Parkinson’s disease (PD) and other chronic illnesses, and Verint Systems Inc. (Nasdaq: VRNT), announced on 11/15/18 the release of UCB’s PD Coach... read more

Thu, 11/15/18 - 09:18 am
admin

Company recognizes sponsors’ achievements in clinical trial reporting with inaugural Clārus Awards

JERSEY CITY, N.J., Nov. 14, 2018 – TrialScope, the global leader in clinical trial... read more

Wed, 11/14/18 - 01:35 pm
dgrabenstein
  • GBM AGILE is backed by more than 150 collaborators around the world
  • GBM treatment options and patient outcomes have remained largely unchanged over several decades and there is no... read more
Wed, 11/14/18 - 09:36 am
admin
  • Bicycle Therapeutics currently has 5 oncology candidates in development
  • The company also has development projects underway outside of the oncology arena


Bicycle... read more

Wed, 11/14/18 - 09:18 am
admin

Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, announced on 11/13/18 that it has completed a $30 million Series A... read more

Wed, 11/14/18 - 12:13 am
admin
  • At 52 weeks, the mean decreases in alkaline phosphatase were -47% and -46% in the 5/10 and 10 mg groups
  • After 26 weeks, the median changes in the pruritus visual analog scale (VAS)... read more
Tue, 11/13/18 - 10:02 am
admin
  • Bipolar disorder affects 5.7 million people in the US alone
  • NRX-101 was previously granted fast track status


NeuroRx, announced on 11/13/18 that it has been granted... read more

Tue, 11/13/18 - 09:01 am
admin
  • PDUFA date set for 1Q 2019
  • This is the first regulatory submission acceptance for a poly ADP-ribose polymerase (PARP) inhibitor in the advanced ovarian cancer 1st-line maintenance... read more
Mon, 11/12/18 - 09:54 am
admin

Prevencio, Inc. announced on 11/12/18 data demonstrating high accuracy for its multiple-protein HART AKITM test. Researchers believe these important findings, presented November 10 at the 2018... read more

Mon, 11/12/18 - 09:51 am
admin


Harpoon Therapeutics, Inc. announced on 11/11/18 the closing of a $70 million Series C equity financing. OrbiMed served as the lead new investor, along with new investors Cormorant, Ridgeback... read more

Sun, 11/11/18 - 09:33 pm
admin

Israeli-based life sciences, healthcare, and technology venture capital firm aMoon is on pace to reach its hard cap of $750 million for its second fund. aMoon was Founded in 2016 by Yar Schindel,... read more

Fri, 11/9/18 - 10:37 am
admin


Oticon Kaizn, the world’s first personal AI assistant for your ears, has received a 2019 CES Best of Innovation Award in the Software and Mobile Apps category, and has been named a CES... read more

Fri, 11/9/18 - 09:48 am
admin
  • In a mouse model, greater than 95% of muscle cells produced the beta-sarcoglycan protein after a single application
  • Myonexus and Sarepta are advancing four additional candidates... read more
Thu, 11/8/18 - 09:56 am
admin

Vedanta Biosciences announced on 11/6/18 preclinical data for VE800, the Company’s orally-administered, live biotherapeutic product candidate in immuno-oncology. The study showed that VE800... read more

Wed, 11/7/18 - 11:15 pm
admin


Synlogic, Inc. (Nasdaq: SYBX) announced on 11/6/18 the presentation of preclinical data from its first immuno-oncology (IO) program at the 33rd Annual Meeting & Pre-Conference Programs of... read more

Wed, 11/7/18 - 11:05 pm
admin

SkinBioTherapeutics plc (AIM: SBTX) announced on 11/7/18 positive data from the first two elements of its human study which focus on skin irritancy and moisturisation potential.

As... read more

Wed, 11/7/18 - 10:53 pm
admin

Pages

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.